This inventor holds 1 USPTO granted patent and 5 published patent applications. Top assignee: Araris Biotech Ag. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Innovations of Philipp Probst in Antibody-Drug Conjugates
Introduction
Philipp Probst is a notable inventor based in Au, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates. His innovative work focuses on enhancing the efficacy of therapeutic agents through advanced conjugation techniques.
Latest Patents
Philipp Probst holds a patent for "Antibody-drug conjugates through specific linker oligopeptides." This invention relates to a method for generating an antibody-payload conjugate using microbial transglutaminase (MTG). The method involves conjugating a linker to a Gln residue in an antibody, utilizing a specific structure that includes various chemical spacers and linking moieties. This innovative approach aims to improve the delivery and effectiveness of therapeutic antibodies.
Career Highlights
Philipp Probst is associated with Araris Biotech AG, a company dedicated to advancing biopharmaceuticals. His work at Araris has positioned him as a key player in the development of novel therapeutic strategies. With a focus on antibody-drug conjugates, he has contributed to the growing field of targeted cancer therapies.
Collaborations
Philipp Probst collaborates with talented professionals in his field, including Philipp Spycher and Isabella Attinger-Toller. These collaborations enhance the research and development efforts at Araris Biotech AG, fostering innovation and progress in biotechnological applications.
Conclusion
Philipp Probst's contributions to the field of antibody-drug conjugates exemplify the importance of innovation in biotechnology. His patent and work at Araris Biotech AG highlight the potential for advancements in targeted therapies.